































































enveloped.	 The	 most	 current	 used	 alternative	 source	 are	 glutamine	 dipeptides.	
Administration	of	glutamine	can	be	supplying	the	artificial	nutrition	support	or	being	
administrated	 independently;	 by	 parenteral	 or	 by	 enteral	 route.	 Traditional	 trials	 of	
glutamine	 supplementation	 demonstrate	 favorable	 results	 in	 patients	 with	 critical	
illness.	However,	newer	trials	which	included	more	study	population,	among	which	the	
REDOX	 trial,	 where	 not	 able	 to	 confirm	 these	 results.	 A	 trend	 towards	 favorable	
outcomes	were	found	in	surgical	and	oncological	patients	with	intravenous	glutamine	
supplementation	 on	 physiological	 doses	 without	 renal	 and/or	 liver	 dysfunction.	 In	
contrast,	there	was	also	found	high	glutamine	baseline	levels	in	a	subgroup	of	critically	








La	 glutamina	 es	 un	 aminoácido	 no	 esencial	 sintetizado	 y	 liberado	 a	 la	 circulación	
sanguínea	 mayoritariamente	 por	 la	 musculatura	 esquelética	 y	 los	 pulmones.	 Los	
enterocitos	 y	 las	 células	 del	 sistema	 inmunitario	 son	 grandes	metabolizadores	 de	 la	
glutamina	 y	 ésta	 es	 crucial	 para	 su	 funcionamiento	 óptimo.	 Debido	 a	 cambios	
metabólicos	 sufridos	 en	 el	 paciente	 crítico,	 los	 niveles	 sanguíneos	 de	 glutamina	
disminuyen	 significativamente	 y	 se	 observa	 una	 depleción	 de	 glutamina	 en	 la	
musculatura	esquelética.	El	tratamiento	con	glutamina	tiene	como	objetivo	normalizar	
los	niveles	plasmáticos	y	mejorar	la	respuesta	del	sistema	inmunitario.	Las	propiedades	
químicas	 de	 la	 glutamina	 son	 desfavorables	 para	 su	 almacenaje	 y	 por	 eso	 se	 han	
desarrollado	 nuevas	 estructuras	 químicas	 de	 glutamina	 para	 ser	 administradas.	 La	








en	dosis	 fisiológicas	que	no	presentaban	 insuficiencia	 renal	y/o	hepática.	En	cambio,	
también	se	han	detectado	en	un	subgrupo	de	pacientes	niveles	elevados	de	glutamina.	







correct	 and	 safe	 utilization	 of	 drugs	 and	 other	 medical	 substances	 through	
pharmaceutical	 care	 and	 intervention;	 inform	 and	 advise	 patients	 about	 their	
treatment,	support	physicians	and	other	healthcare	professionals	by	 informing	about	
the	 rational	 use	 of	 medication,	 conduct	 observational	 studies	 and	 clinical	 trials	 of	
therapeutic	 effects	 and	 educate	 civilization	 to	 promote	 health	 and	 prevent	 disease.	
These	are	just	some	of	the	clinical	pharmacist	responsibilities.		
Hospital	pharmacy,	a	branch	of	clinical	pharmacy,	has	further	specific	functions	in	the	



























Critically	 ill	 patients	 are	mostly	 not	 able	 to	 eat	 (enough)	 by	 themselves,	 so	 artificial	
nutrition	support,	defined	as	the	administration	of	nutrient	solutions	by	the	enteral	or	
intravenous	(parenteral)	routes,	is	required	to	supply	all	or	the	remainder	part	of	the	
patients’	 needs.	 Enteral	 nutrition	 support	 is	 preferred.	 Parenteral	 nutrition	 is	 only	
indicated	when	enteral	route	is	contraindicated	(e.g.	in	case	of	gastric	complications)	or	
fails	to	cover	the	patients’	requirements1.	
Until	 now,	 controversy	 persists	 in	 defining	 adequate	 nutrition	 support.	 Guidelines	
between	 hospital	 settings	 vary	 in	 timing,	 caloric	 quantity,	 protein	 needs,	
monetarization,	 use	 of	 adjuvant	 therapies	 such	 as	 probiotics	 or	 immunonutrition,	
support	during	specific	conditions,	etc.	Many	clinical	 trials	are	performed	 in	order	 to	
clarify	 findings	 and	 to	 develop	 recommendations	 for	 adequate	 nutrition	 support	
practice,	including	for	particular	nutrients,	such	as	glutamine.				
Glutamine	 is	 the	most	abundant	 free	amino	acid	 found	 in	 the	human	body	pool	and	
blood	stream.	In	a	healthy	man,	the	plasma	values	range	between	450	and	650	µmol/L	
although	 intracellular	 levels	are	25-30	 times	greater.	Glutamine	 is	 considered	a	non-





illness)	 different	 human	 defense	 systems	 increase	 their	 glutamine	 consumption	 and	
overcome	the	endogenous	synthesis	capacity,	causing	glutamine	muscle	depletion	and	
low	 plasma	 levels.	 Glutamine	 becomes	 essential	 and	 therefore	 it’s	 considered	 a	
conditionally	essential	amino	acid2.	
In	order	to	cover	the	metabolic	deficiency	and	to	let	critically	ill	patients	benefit	from	
different	 glutamine	 functions,	 randomized	 clinical	 trials	 have	 been	 performed	 with	
glutamine	supplementation.	Most	of	the	earlier	small	trials	using	parenteral	glutamine	







individual	 nutrient	 regimes	 to	 optimize	 immune	 function	 and	 cell	 recovery.	 Those	





(REDOX)	 trial6,	 the	results	were	not	as	expected.	This	 trial	 fails	 in	 finding	any	benefit	
















• To	 figure	 out	 the	 potential	 beneficial	 implications	 of	 glutamine	 in	 critically	 ill	
patients.	
• To	understand	the	process	of	glutamine	supplementation	in	the	routine	clinical	
practice,	 from	 preparation	 to	 administration,	 and	 the	 different	 associated	
problems.	












was	 performed	 between	 February	 and	May	 2017.	 PubMed,	 a	 free	 research	website	
connected	 to	 the	Medical	 Literature	Analysis	and	Retrieval	 System	online	 (MEDLINE)	
database,	which	contains	the	most	relevant	publications	in	the	setting	of	life	science	and	





First,	 an	exhaustive	bibliographic	 search	of	background	 information	about	 glutamine	
and	critical	illness	was	carried	out	to	understand	and	interpret	the	results	of	the	later	
included	 clinical	 trials.	 Some	 of	 the	 main	 keywords	 utilized	 in	 this	 research	 were	
“glutamine”	 in	 combination	 with	 “physiology”,	 “functions”,	 “critical	 illness”,	
“metabolism”,	“preparation”	and	“kinetics”.	From	these	first	found	articles,	new	sources	
of	interest	were	provided	from	its	bibliography.		





in	 combination	 of	 “parenteral”,	 “supplementation”,	 “administration”,	 “nutrition”,	
“support”,	“intravenous”,	“critically	ill	patients”,	“critical	illness”	and	“ICU”,	applying	the	
search	filters	“clinical	trial”	and	“meta-analysis”.	More	clinical	trials	were	extracted	from	




Finally,	 commentaries	 on	 the	 REDOX	 trial	 and	 other	 recent	 literature	 reviews	 of	














catalyzing	 the	 condensing	 reaction	of	 glutamate	and	ammonia	 (NH4+)	 in	presence	of	
adenosine	 triphosphate	 (ATP).	 This	 cytosolic	 enzyme	 is	mostly	 found	 in	 the	 skeletal	
muscle	and	lungs2.	𝐺𝑙𝑢𝑡𝑎𝑚𝑎𝑡𝑒 + 𝐴𝑇𝑃 + 𝑁𝐻./ → 𝐺𝑙𝑢𝑡𝑎𝑚𝑖𝑛𝑒 + 𝐴𝐷𝑃 + 𝑃𝑖	
On	the	other	hand,	glutamine	is	hydrolyzed	by	the	mitochondrial	glutaminase	obtaining	
glutamate	 and	 ammonia.	 Rapidly	 dividing	 cells,	 like	 enterocytes	 and	 some	 immune	
system	cells,	present	a	high	activity	of	this	enzyme	and	are	consequently	great	glutamine	
consumers2.	 𝐺𝑙𝑢𝑡𝑎𝑚𝑖𝑛𝑒 + 𝐻4𝑂 → 𝐺𝑙𝑢𝑡𝑎𝑚𝑎𝑡𝑒 + 𝑁𝐻./	
The	metabolism	of	glutamine	depends	on	the	presence	and	activity	of	both	enzymes.	
Both	are	dispersed	differently	along	the	human	body	and	so	glutamine	production	and	
consumption	 differs	 between	 tissues.	 In	 physiological	 conditions,	 there	 is	 a	 balance	
between	 both	 reactions	 and	 the	 homeostasis	 of	 glutamine	 is	maintained.	 However,	
some	 psychopathological	 conditions	 can	 lead	 to	 a	 shortage	 of	 glutamine	 with	
consequently	harmful	effects	on	high-consume	tissues2,7.		1.2	Metabolic	pathways	
Glutamine	 acts	 as	 nitrogen	 and	 carbon	 skeletal	 source	 in	 order	 to	maintain	 the	 cell	






Figure	 1.	 Overview	 of	 glutamine	 and	 glutamate	 metabolism.	 Glutamate	 is	 produced	 from	
glutamine	 through	glutaminase	activity.	Glutamate	can	be	converted	 into	glutamine	 through	








As	 the	 implied	 enzymes	 in	 the	 metabolism	 of	 glutamine	 and	 the	 related	 metabolic	
pathways	 vary	 hardly	 between	 tissues,	 glutamine	 has	 not	 the	 same	 importance	 to	


















The	 net	 flux	 depends	 on	 the	 body	 needs	 and	 state	 at	 each	 moment,	 as	 glutamine	





making	 glutamine	 an	 especially	 important	 factor	 for	 the	 correct	 cell	 function.	 Gut	









have	 a	 10-fold	 greater	 glutamine	 utilization	 compared	with	 resting	 cells9.	 Glutamine	
provides	 the	 immune	 system	 metabolic	 intermediates	 for	 synthesis	 of	 purines	 and	
pyrimidines	and	is	used	as	energy	source4.	
Nevertheless,	 glutamine	 has	 other	 essential	 functions	 related	 to	 cell	 survival	 during	
stress.	Glutamine	stimulates	the	expression	of	heat	shock	proteins	(HSP),	which	are	a	
group	of	proteins	which	enhance	cellular	survival	in	stressful	situations10.	Glutamine	and	
glutamate	 are	 also	 precursors	 for	 glutathione	 synthesis	 which	 play	 a	 role	 in	 the	
antioxidant	defenses	of	the	cells11.	
Kidneys	 are	 small	 consumers	 of	 glutamine,	 where	 it’s	 used	 mostly	 for	 renal	
gluconeogenesis	 and	 ammoniagenesis.	 New	 synthetized	 ammonia	 is	 excreted	 and	
linked	to	increased	acid	excretion,	helping	to	sustain	the	acid-base	balance.	In	acidosis	






Therefore,	 when	 liver	 and	 renal	 functions	 are	 impaired,	 the	 level	 of	 glutamine	 and	
ammonia	in	plasma	increases	and	becomes	harmful4.		2	Critical	illness	2.1	Metabolic	changes	
Critical	 illness	 is	paired	with	an	adaptive	stress	 response.	This	 typical	and	complicate	
response	 implies	changes	 in	neuroendocrine	pathways,	 including	an	activation	of	the	
sympathetic	 nervous	 system	 and	 the	 hypothalamus-pituitary	 axis	 which	 results	 in	
increased	circulating	levels	of	stress	hormones,	such	as	corticoids	and	catecholamines.	
Besides,	 inflammation	 mediators	 and	 cytokines	 are	 produced	 in	 high	 quantities.	 All	
these	 chemical	 changes	 affect	 the	 metabolic	 state	 of	 the	 patient,	 leading	 to	 a	
generalized	catabolic	state	with	resistance	to	anabolic	signals	(such	as	insulin)12.		
Clinically,	those	patients	with	stress	induced	metabolism	have	variations	in	their	energy	
expenditure,	 use	 different	 sources	 of	 energy	 substrates,	 suffer	 from	 stress	














However,	 the	 endogenous	 glutamine	 production	 becomes	 insufficient	 and	 skeletal	
muscle	spends	glutamine	from	the	intracellular	pool	and	by	breaking	down	own	muscle	
proteins,	 promoted	 by	 the	 overall	 catabolic	 state.	 The	 human	 body	 reservoir	 of	
glutamine	becomes	depleted	as	the	increased	requirements	overcome	the	muscle	and	















Doses	 of	 glutamine	 administration	 above	 the	 patient	 requirements	 or	 glutamine	




























4. Sterilize	 by	 filtration	 through	 a	 sterile	 0.22	µm	 filter	 into	 a	 sterile	 collection	
vessel.		
Glutamine	 solution	 can	 be	 administrated	 independently	 through	 an	 intravenous	
infusion	 line	 or	 added	 to	 the	 parenteral	 nutrition	 bag	 as	 the	 standard	 amino	 acids	
formulas	and	“all-in-one”	parenteral	nutrition	bags	do	not	contain	free	glutamine.	











dipeptides,	 alanyl-glutamine	 or	 glycyl-glutamine,	 are	 hydrolyzed	 rapidly	 after	
intravenous	administration,	being	an	adequate	source	of	free	glutamine.	Those	
dipeptides	 are	 stable	 during	 prolonged	 storage	 periods	 in	 aqueous	 solutions.	









• Branched-chain	 amino	 acids	 are	 essential	 amino	 acids	 that	 serve	 as	 essential	
substrates	and	regulators	 in	 the	synthesis	of	body	proteins	and	represent	the	







in	 water	 solutions.	 Nonetheless,	 glutamate	 is	 not	 used	 as	 it	 hardly	 passes	
through	cell	membranes	and	high	doses	can	cause	neurotoxic	side	effects.	
	
Figure	 4.	 Relation	 between	 glutamine	 production,	 branched-chain	 amino	 acids,	 alfa-
ketoglutarate	and	glutamate.	BCAA:	branched-chain	amino	acids.	BCKA:	branched-chain	keto	







or	 integrated	 in	 the	 artificial	 nutrition	 solution.	 Intolerance	 to	 enteral	 feeding	 is	 a	
common	finding	in	critically	ill	patients	and	the	glutamine	absorption	is	low	due	to	the	
strong	 first	 pass	 metabolism	 in	 the	 intestine;	 consequently,	 enteral	 glutamine	
supplementation	 is	 not	 so	 beneficial	 because	 most	 of	 the	 administrated	 glutamine	
doesn’t	reach	the	systemic	circulation.	In	fact,	enteral	glutamine	delivery	preferentially	
increases	glutamine	disposal	in	the	enterocytes	and	intestine	immune	cells8.		
When	 given	 intravenously,	 plasma	 glutamine	 concentration	 increases	 by	 70%	 by	
intravenous	 infusion	 of	 exogenous	 glutamine	 dipeptide20.	 In	 spite	 the	 fact	 that	
glutamine	 is	 able	 to	 normalize	 plasma	 glutamine	 concentration,	 glutamine	
supplementation	 does	 not	 attenuate	 depletion	 of	 muscle	 free	 glutamine	 neither	
increases	the	intracellular	storage20,21.	5	Guidelines	and	recommendations	
The	 European	 Society	 for	 Clinical	 Nutrition	 and	 Metabolism	 (ESPEN)	 is	 a	 scientific	
organization	 dedicated	 to	 all	 relevant	 issues	 in	 the	 field	 of	 clinical	 nutrition	 and	
metabolism	 and	 promotes	 the	 clinical	 research	 of	 parenteral	 and	 enteral	 nutrition	
support.	The	ESPEN	publishes	guidelines	and	position	papers	about	recommendations	
for	clinical	nutrition	practices	at	a	regular	basis.	
The	 ESPEN	 guideline	 on	 parenteral	 nutrition	 in	 the	 intensive	 care	 published	 in	 2009	
recommended	adding	0.2-0.4	g/kg/day	of	 intravenous	glutamine	(0.3-0.6	g/kg/day	of	
alanyl-glutamine	 dipeptide)	 when	 parenteral	 nutrition	 is	 indicated,	 which	 is	 given	 a	
grade	A	 of	 evidence.	When	 glutamine	 cannot	 be	 incorporated	within	 the	 parenteral	
nutrition	itself,	it	can	be	administered	through	an	intravenous	line22.	
The	American	Society	for	Parenteral	and	Enteral	Nutrition	(ASPEN)	published	a	position	




However,	 past	 2016,	 the	 ASPEN	 published	 new	 guidelines	 for	 the	 provision	 and	
assessment	 of	 nutrition	 support	 therapy	 in	 the	 adult	 critically	 ill	 patient	where	 they	
recommended	 with	 moderate	 evidence	 based	 on	 the	 newer	 reported	 results	 of	
randomized	 trials	 that	 parenteral	 glutamine	 supplementation	 should	 not	 be	 used	
routinely	in	the	critical	care	setting24.		
The	 Canadian	 Clinical	 Practice	 Guidelines	 (CCPG)	 from	 2003	 of	 nutrition	 support	 in	




supplementation	 with	 glutamine	 but	 not	 intravenous	 glutamine	 supplementation	 in	
critically	ill	patients	receiving	enteral	nutrition	due	to	insufficient	data25.	The	updated	
guideline	 of	 2015,	 however,	 changes	 their	 setting	 to:	 “when	 parenteral	 nutrition	 is	
prescribed	 to	 critically	 ill	 patients,	 we	 recommend	 parenteral	 supplementation	with	
glutamine	NOT	be	used”.		
Evidence-based	guidelines	are	systematically	developed	statements	based	on	published	








be	 logical	 that	 critically	 ill	 patients	 should	 obtain	 some	 benefit	 on	 exogenous	
replacement.	
Many	 of	 the	 early	 studies	 demonstrated	 significant	 improvement	 on	 outcomes,	
including	lower	mortality	rates,	reduction	in	infection	rates	and	less	hospital	length	of	




of	 glutamine	 supplementation	with	 parenteral	 nutrition.	 These	 studies,	 due	 to	 their	
similar	study	protocol,	can	be	considered	as	“traditional	glutamine	trials”.		
For	example,	in	2001,	Wischemeyer	et	al.26	conducted	a	randomized	trial	of	glutamine	


























examined	 in	 different	meta-analysis	 to	 determine	 a	more	 precise	 estimation	 of	 the	
effects	of	glutamine	treatment	on	patients’	outcomes.	
Bollhalder	et	al.33	included	forty	randomized	clinical	trials	(RCT)	that	were	published	in	
the	period	between	1990	and	2012.	 The	 results	 concluded	a	 significant	 reduction	of	
infectious	complications,	a	shortening	in	hospital	LOS	but	no	significant	reduction	of	the	
short-term	and	6-month	mortality.	Although,	when	they	considered	only	doses	above	
0.2	 g/kg/day	with	 a	 duration	of	more	 than	nine	days	 of	 glutamine	 administration,	 a	
significant	reduction	of	short	term	mortality,	infections	and	hospital	length	of	stay	were	
found,	concluding	 that	glutamine	dose	and	duration	of	administration	 influences	 the	










until	 now,	 largest	 multicenter	 randomized	 clinical	 trial	 in	 evaluating	 the	 efficacy	 of	





The	 field	 of	 pharmaconutrition	 can	 be	 understood	 as	 using	 nutrients	 in	 a	
pharmacological	way	and	not	simply	for	restoring	nutrient	deficiency.		
In	total,	1223	critically	 ill	patients	around	the	world	which	present	multiorgan	failure	




The	 results	 found	were	 in	 contradiction	with	 the	 initial	 propounded	hypothesis.	 The	
group	receiving	glutamine	supplementation	shows	a	trend	towards	an	increased	28-day	
mortality	 and	 significant	 higher	 hospital	 mortality	 and	 6-month	 mortality.	 On	 side,	
glutamine	had	no	beneficial	effect	on	rates	of	organ	failure	or	infectious	complications.		
The	REDOX	trial	was	followed	by	a	post-hoc	analysis	published	by	the	same	authors35.	
The	 aim	 of	 this	 study	 was	 to	 evaluate	 the	 effect	 of	 glutamine	 supplementation	 in	
different	subgroups	of	baseline	characteristics.		
The	28-day	mortality,	the	primary	outcome	of	the	study,	was	only	significantly	increased	
in	 patients	who	 presented	 renal	 failure	 at	 baseline.	 Glutamine	 intervention	was	 not	
associated	with	 harm	 or	 benefit	 in	 patients	without	 baseline	 renal	 dysfunction.	 The	
harm	 caused	 of	 glutamine	 supplementation	 in	 patients	 with	 renal	 impairment	 was	
attenuated	in	the	presence	of	dialysis,	with	could	help	in	preventing	the	accumulation	
of	glutamine	or	other	harmful	metabolites	derivate	from	glutamine.				
In	 conclusion,	 the	 authors	 of	 the	 REDOX	 trial	 recommended	 to	 be	 cautious	 when	
providing	high-dose	glutamine	supplementation	to	critically	ill	patients	with	multiorgan	
failure,	 particularly	 to	 patients	 with	 renal	 failure	 but	 their	 results	 should	 not	 be	
generalized	to	the	rest	of	ICU	patients	who	can	have	some	benefit	in	lower	doses.	6.3	Understanding	the	REDOX	trial	





The	REDOX	 trial	 is	 based	on	 a	 completely	 new	way	of	 glutamine	utilization	 as	 some	
points	of	their	study	protocol	differed	most	of	the	previous	studies	which	could	have	
promoted	the	discrepancies	in	results	found	between	them:		
• A	 combination	 of	 glutamine	 supplementation	 by	 enteral	 and	 intravenous	










supraphysiologic	 dose,	 understood	 as	 delivering	 glutamine	 in	 amounts	 that	
exceed	the	naturally	glutamine	production	of	the	body,	was	 justified	with	the	
underlying	 idea	 of	 glutamine	 being	 a	 pharmaconutrient	 or	 immunonutrient	
rather	than	just	a	part	of	the	nutrition	support.	Nonetheless,	this	dosage	can	lead	
to	unknown	adverse	effects	and	have	a	negative	impact	on	the	patient’s	health.		
• Glutamine	 treatment	 started	 within	 24	 hours	 after	 the	 ICU	 admission	
corresponding	to	the	acute	phase	of	critical	illness.	The	intention	was	preventing	







treatments,	 however,	 confuse	 as	 findings	 can	 be	 caused	 by	 glutamine,	
antioxidants	or	by	the	interaction	of	supplying	both	together	(e.g.	glutamine’s	
positive	effects	could	have	been	blocked	or	countered	by	antioxidants).		









benefit	 from	 glutamine	 supplementation	 when	 they	 are	 underfed	 because	
inadequate	 clinical	 nutrition	 significantly	 affects	 the	 outcomes	 in	 case	 of	 ICU	
patients.	








Table	 1.	 Principal	 differences	 between	 traditional	 glutamine	 supplementation	 trials	 and	 the	
REDOX	trial.	






Patients	 with	 enteral	 or	
parenteral	nutrition	regimens	





Mixed	 together	 with	 artificial	
nutrition	 support	 (mostly	
parenteral)	
Separate	 from	 the	 nutrition	




Later	 in	 the	 course	 of	 ICU	
admission	















was	significantly	 lower	than	 in	the	control	group.	No	shortening	was	observed	 in	the	
hospital	length	of	stay	in	the	glutamine	supplemented	group.		
Sub-group	meta-analyses	were	 performed	 simultaneously	 to	 estimate	 the	 effects	 of	
glutamine	in	specific	patient	populations,	the	effects	related	to	a	specific	dosage	and	
the	 effects	 related	 to	 the	 nutritional	 supplementation	 method.	 Glutamine	 effects	

















of	 glutamine	 on	 infection	 rates.	 In	 their	 subgroup	 analysis,	 they	 could	 observe	 a	
protective	 roll	 of	 glutamine	 administrated	 intravenously	 for	 more	 than	 five	 days	 in	
patients	with	a	low	Acute	Physiology	and	Chronic	Health	disease	Classification	System	II	
(APACHE)	score	below	15.	
The	 differences	 in	 findings	 between	 the	 pre-REDOX	 and	 post-REDOX	 realized	meta-
analyses	were	mostly	due	to	the	inclusion	of	results	of	the	REDOX	trial.	All	three	meta-










60%	 presented	 low	 baseline	 glutamine	 which	 significant	 increase	 in	 the	 glutamine	
supplementation	group	compared	to	the	non-glutamine	supplementation	group	after	
six	 days	 of	 treatment.	 Nevertheless,	 glutamine	 supplementation	 within	 the	
recommended	 guidelines	 dose	 was	 insufficient	 to	 normalize	 the	 levels	 of	 plasma	
glutamine	 in	 many	 patients	 which	 could	 explain	 the	 lack	 of	 effect	 in	 glutamine	

















clinical	 trials	which	 all	 strictly	 delivered	 glutamine	 supplementation	 according	 to	 the	
current	 clinical	 ESPEN	 guidelines:	 critically	 ill	 patients	 without	 hepatic	 and/or	 renal	
failure,	hemodynamically	 and	metabolically	 stablished	were	administrated	glutamine	




glutamine	administration	according	 to	 the	2009	ESPEN	guidelines22	 reduces	 infection	
complications,	the	ICU	and	hospital	 length	of	stay,	the	number	of	days	of	mechanical	
ventilation	and	hospital	mortality	rate.		7	The	role	of	glutamine	in	the	ICU	
Positive	 evidence	 in	 support	 of	 intravenous	 glutamine	 supplementation	 comes	 from	
small	single-center	trials	which	are	individually	inconclusive.	These	traditional	glutamine	
trials	 include	small	sample	sizes	of	population	and	are	so	exposed	to	the	small	study	



















































Surgical	 ICU	 patients,	 including	 burns	 injury	 and	 trauma	 patients,	 are	more	 likely	 to	






low	 baseline	 glutamine	 levels.	 Several	 newer	 studies	 started	 to	 record	 glutamine	
baseline	 levels	 but	 could	 only	 confirm	 glutamine	 deficiency	 in	 part	 of	 the	 study	





could	 not	 be	 concluded	 in	 all	 trials.	 Curiously,	 some	 critically	 ill	 patients	 present	
remarkably	elevated	baseline	levels,	above	the	physiological	upper	limit	maybe	due	to	
the	increased	muscle	release	or	decreased	liver	uptake	and	metabolism.	High	baseline	
glutamine	 has	 also	 been	 found	 to	 be	 a	 risk	 factor	 for	 mortality.	 Glutamine	
supplementation	 in	 patients	 with	 high	 baseline	 glutamine	 levels	 would	 probably	


























physiological	dose.	But	 it’s	not	 clear	 if	 this	 is	enough	 to	normalize	glutamine	 related	
physiological	 functions	 and	 to	 improve	 the	 immune	 system.	 Besides,	 depletion	 of	
intracellular	muscle	glutamine	is	not	attenuated	by	an	exogenous	glutamine	infusion.		




consistent	 as	 parenteral	 administration	 and	 do	 not	 increase	 that	 much	 the	 plasma	
levels.	 The	 recent	 published	MetaPlus	 trial43	 didn’t	 help	 to	 firm	 benefits	 of	 enteral	
administration	 as	 the	 intervention	 group,	 fed	 with	 enriched	 enteral	 nutrition	 with	




of	 ICU	 admission,	 as	 parenteral	 nutrition	 is	 not	 the	 first	 chosen	 option	 to	 cover	
nutritional	 requirements	 in	 the	 critically	 ill	 patients.	 Pharmacological	 glutamine	
administration	is	designed	to	be	started	at	admission	to	the	ICU,	without	taking	account	
if	 the	 patient	 receives	 enteral	 or	 parenteral	 nutrition.	 Patient’s	 state	 and	 degree	 of	
illness	differ	 in	 early	 and	 later	phases	of	 ICU	 stay	 and	 so	 the	 glutamine	efficacy	 and	
toxicity	 can	 vary	 between	 “early”	 and	 “late”	 start	 of	 supplementation.	 Onside,	 by	
choosing	only	patients	needing	parenteral	nutrition	support,	a	subgroup	of	critically	ill	







Trials	 are	 performed	 on	 the	 hypothesis	 that	 apparent	 glutamine	 deficiency	
compromises	 an	 adequate	 immune	 system	 function	 and	 cell	 survival	 and	 therefore	






conditional	deficiency.	Administration	of	exogenous	glutamine	could	 interfere	 in	 this	
favorable	response	and	so	worsen	outcomes.		
Maybe	glutamine	plays	a	role	in	several	prior	mentioned	physiological	functions	and	its	
depletion	 is	 a	 marker	 of	 disease	 severity	 but	 exogenous	 supplementation	 and	
enhancement	 of	 plasma	 levels	 is	 not	 determinant	 to	 improve	 outcomes.	 Maybe	
decreased	 glutamine	 levels	 just	 reflect	 the	 typical	 global	 protein	 depletion	 without	
having	any	essential	function	for	critically	ill	patients.		





evidence	 interpretation	 vary	widely	 between	 different	 authors.	 The	 REDOX	 trial	 has	
mostly	contributed	 to	question	 the	scientific	 recommendations	published	until	2013.	
Currently,	 glutamine’s	 use	 according	 to	 the	 ESPEN	 guidelines	 seems	 to	 be	 the	most	
effective	and	safe	way	of	glutamine	delivery.		
In	 this	 same	 line,	 optimal	 nutrition	 support	 for	 critically	 ill	 patients	 remains	
controversial.	 It’s	 difficult	 to	 predict	 energy	 expenditure	 and	 protein	 needs	 in	 those	
patients	 due	 to	 the	 complex	 and	 variable	 metabolic	 alterations	 suffered.	 Artificial	
nutrition	support	and	intravenous	glutamine	supplementation	are	still	unphysiological	
ways	of	feeding	and	not	without	complications.	In	overall,	the	optimal	amount,	route	




to	 define	 safe	 and	 effective	 regimens	 of	 glutamine	 supplementation	 and	 the	 right	
specific	subgroups	of	patients	who	potentially	may	benefit	from	this	treatment.	The	next	
questions	 should	 be	 further	 investigated	 in	 order	 to	 propose	 new	 valid	
recommendations:	
• Which	patients	present	 low	baseline	glutamine	 levels,	 taking	 into	account	the	
underlying	disease,	illness	severity	and/or	nutritional	baseline	status?	


























and	 stability.	 New	 delivery	 sources,	 like	 glutamine	 containing	 dipeptides	
included	in	commercial	amino	acid	solutions,	are	currently	more	popular	and	are	
easy	ways	to	include	glutamine	supplementation	to	the	regular	use.	
• Traditional	 studies	 associate	 glutamine	 supplementation	 with	 beneficial	
treatment	 effects,	 however	 newer	 and	 more	 scientific	 robust	 trials,	 as	 the	
REDOX	 trial,	 found	 contradictory	 results,	 questioning	 glutamine	
supplementation	 efficacy.	 Consequently,	 some	 big	 and	 important	 guidelines	
have	changed	their	recommendations.	
• Some	 patients’	 characteristics	 and	 glutamine	 regimen	 aspects	 promote	
beneficial	 treatment	 effects	 of	 glutamine	 while	 other	 aspects	 show	 more	
prejudicial	 effects.	 New	 trials	 should	 further	 investigate	 how	 these	 different	
points	influence	the	glutamine	efficacy.			
• Not	 all	 critically	 ill	 patients	 have	 low	 baseline	 glutamine	 and	 some	 have	
conversely	an	increased	plasma	level,	being	both	an	independent	predictor	of	
mortality.	Correcting	the	deficient	state	seems	to	be	logically	a	better	target	than	
over	 supplementing	non-deficient	 patients.	 Therefore,	 determining	 glutamine	
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